2023 World Conference on Lung Cancer (Posters)-EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review

EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of a targeted literature review that aimed to assess the risk of heart failure (HF) associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). The review identified 82 publications related to HF, with 3 reporting HF events in patients with any cancer treated with TKIs and 79 reporting HF events in patients with NSCLC treated with EGFR TKIs. <br /><br />The review found that there were no reported cases of HF in two studies involving patients with any type of cancer treated with TKIs. In another study, the incidence of HF or cardiomyopathy was reported to be 13 per 1000 person-years. In patients with NSCLC treated with EGFR TKIs, most studies did not observe any HF events or instances of HF mortality. Among the publications that evaluated specific EGFR TKIs, some reported no HF events or deaths due to HF, while others reported a range of HF incidence and mortality rates.<br /><br />The review highlights the importance of monitoring patients for signs of cardiotoxicity, particularly related to HF, when treated with EGFR TKIs. However, it concludes that there is limited evidence of HF events or mortality after treatment with TKIs, particularly in patients with NSCLC. The limitations of the review include the language restriction to English publications and the variation in treatment guidelines and drug availability across different regions.<br /><br />Overall, the review suggests that the risk of HF associated with EGFR TKIs in patients with NSCLC appears to be low. However, further research is needed to establish standardized definitions of HF-related events and improve monitoring for HF in patients with cancer.

Asset Subtitle

Bilal Khokhar

Meta Tag

Speaker Bilal Khokhar

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

heart failure

epidermal growth factor receptor

EGFR

tyrosine kinase inhibitors

TKIs

non-small cell lung cancer

NSCLC

cardiotoxicity

monitoring